These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Is It Possible to Intervene in the Capacity of Ramírez-Toloza G; Aguilar-Guzmán L; Valck C; Menon SS; Ferreira VP; Ferreira A Front Immunol; 2021; 12():789145. PubMed ID: 34975884 [TBL] [Abstract][Full Text] [Related]
11. Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas' disease. Norris KA; Galvão LM; Schrimpf JE; Cançado JR; Krettli AU Infect Immun; 1994 Sep; 62(9):4072-4. PubMed ID: 8063427 [TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin. Sosoniuk E; Vallejos G; Kenawy H; Gaboriaud C; Thielens N; Fujita T; Schwaeble W; Ferreira A; Valck C Mol Immunol; 2014 Jul; 60(1):80-5. PubMed ID: 24769495 [TBL] [Abstract][Full Text] [Related]
13. Trypanosoma cruzi carrying a monoallelic deletion of the calreticulin (TcCRT) gene are susceptible to complement mediated killing and defective in their metacyclogenesis. Sánchez Valdéz FJ; Pérez Brandán C; Zago MP; Labriola C; Ferreira A; Basombrío MÁ Mol Immunol; 2013 Mar; 53(3):198-205. PubMed ID: 22954747 [TBL] [Abstract][Full Text] [Related]
14. Macrophages in experimental Chagas' disease. Kuhn RE Immunol Ser; 1994; 60():495-502. PubMed ID: 8251589 [TBL] [Abstract][Full Text] [Related]
15. Roles of Trypanosoma cruzi calreticulin in parasite-host interactions and in tumor growth. Ramírez G; Valck C; Aguilar L; Kemmerling U; López-Muñoz R; Cabrera G; Morello A; Ferreira J; Maya JD; Galanti N; Ferreira A Mol Immunol; 2012 Oct; 52(3-4):133-40. PubMed ID: 22673211 [TBL] [Abstract][Full Text] [Related]
16. Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Ramírez G; Valck C; Molina MC; Ribeiro CH; López N; Sánchez G; Ferreira VP; Billetta R; Aguilar L; Maldonado I; Cattán P; Schwaeble W; Ferreira A Immunobiology; 2011; 216(1-2):265-73. PubMed ID: 20472323 [TBL] [Abstract][Full Text] [Related]
18. Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Egui A; Thomas MC; Morell M; Marañón C; Carrilero B; Segovia M; Puerta CJ; Pinazo MJ; Rosas F; Gascón J; López MC Mol Immunol; 2012 Oct; 52(3-4):289-98. PubMed ID: 22750229 [TBL] [Abstract][Full Text] [Related]
19. [Immune response to Trypanosoma cruzi. An approach to the pathogenesis of Chagas' disease]. Braun M; de Titto E Acta Physiol Pharmacol Latinoam; 1985; 35(1):1-47. PubMed ID: 2932884 [TBL] [Abstract][Full Text] [Related]
20. Trypanosoma cruzi-infected macrophages are defective in major histocompatibility complex class II antigen presentation. La Flamme AC; Kahn SJ; Rudensky AY; Van Voorhis WC Eur J Immunol; 1997 Dec; 27(12):3085-94. PubMed ID: 9464791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]